Supreme Court considers taking on pay-to-delay

12/7/2012 | Bloomberg

The Supreme Court is poised to announce whether the justices will hear a case regarding drugmaker deals to delay market entry of generic drugs. The Federal Trade Commission and the Department of Justice say such deals violate antitrust laws, but drugmakers say the deals are legal exercises of patent rights and are good for innovation.

View Full Article in:

Bloomberg